October 18, 2017

Five Prime to Present Preclinical Data on FPT155 at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that it will feature new preclinical data on FPT155, its novel therapeutic CD80-Fc fusion protein, in a poster presentation at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference is scheduled to take place October 26-30, 2017, in Philadelphia, and abstracts may now be viewed online through the itinerary planner.

Abstract Number and Title: B005 - "FPT155, a novel therapeutic CD80-Fc fusion protein, with potent anti-tumor activity in preclinical models"
Session Title: Session PO.B01 - Immune Modulators
Session Date and Time: Sunday, October 29, 2017, 12:30 - 4:00 PM
Location: Hall E, Philadelphia Convention Center 

About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.

Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

CONTACT
Derek Cole
Investor Relations Advisory Solutions
720-785-4497
derek.cole@iradvisory.com

 

Primary Logo

Source: Five Prime Therapeutics, Inc.

News Provided by Acquire Media


Close window | Back to top

Copyright 2017 Five Prime Therapeutics, Inc.